Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | HTR2C | P28335 | 7/20 | 0.39 |
| ▸ | HTR2B | P41595 | 7/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16691535 | 1.00 | ACHE (0.52) | ACHETSHRMETAP1NOS3NOS2 | |
| SCHEMBL6498697 | 0.80 | ACHE (0.35) | ACHETSHRBRD4CREBBPSMN1; SMN2 | |
| SCHEMBL10346331 | 0.77 | ACHE (0.43) | ACHETSHRMETAP1HTR2AHTR2C | |
| SCHEMBL414650 | 0.72 | CYP3A4 (0.44) | TSHRSIGMAR1 | |
| SCHEMBL28355730 | 0.72 | ACHE (0.41) | ACHETSHRMETAP1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL28152573 | 0.71 | CYP3A4 (0.43) | TSHRSIGMAR1 | |
| Benzene SCHEMBL28485309 | 0.71 | SIGMAR1 (0.44) | TSHRSIGMAR1 | |
| SCHEMBL9752693 | 0.68 | ACHE (1.00) | ACHETSHRMETAP1NOS3NOS2 | |
| SCHEMBL4938272 | 0.68 | ACHE (1.00) | ACHETSHRMETAP1NOS3NOS2 | |
| SCHEMBL29661169 | 0.68 | NPSR1 (0.50) | HTR2AHTR2CHTR2BSIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | ACHE 953/4885TSHR 3442/4885METAP1 2774/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | ACHE 4776/4885TSHR 4317/4885METAP1 2829/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | ACHE 7/4885TSHR 4760/4885METAP1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.